6 completed. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 1 | Completed 1 |
Follow ARRY-334543: new trials by email Literature Review of ARRY-334543 trials Research Report on ARRY-334543
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine ASLAN001, cisplatin + capecitabine, cisplatin + 5-fluorouracil (or+ Leucovorin) - Solid Tumor | Phase 1 | Completed | ASLAN Pharmaceuticals | 31 | 2014-08-05 | 2018-10-25 |
| A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Gemcitabine, nucleoside analogue; intravenous - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2009-03-01 | 2012-10-04 |
| A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Docetaxel, mitotic inhibitor; intravenous, Prophylactic growth factors; subcutaneous - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 27 | 2009-01-01 | 2020-10-06 |
| A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Capecitabine, 5-fluorouracil prodrug; oral - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 29 | 2008-06-01 | 2020-10-06 |
| A Study of ARRY-334543 in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 31 | 2008-02-01 | 2020-10-08 |
| A Study of ARRY-334543 in Patients With Advanced Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral - Advanced Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 96 | 2006-01-01 | 2020-10-14 |
Array Biopharma, now a wholly owned subsidiary of Pfizer (4) · ASLAN Pharmaceuticals (1) · Array BioPharma (1)
United States (4) · Canada (3) · Hong Kong (1) · Taiwan (1)